Cyclacel Pharmaceuticals, Inc. (CYCC)
NASDAQ: CYCC · Real-Time Price · USD
16.04
-1.11 (-6.47%)
At close: Jul 25, 2025, 4:00 PM
16.06
+0.02 (0.12%)
After-hours: Jul 25, 2025, 7:59 PM EDT
Cyclacel Pharmaceuticals Stock Forecast
Stock Price Forecast
There is currently no analyst price target forecast available for Cyclacel Pharmaceuticals.
Price Target: n/a
Analyst Consensus: n/a
Analyst Ratings
There are currently no analyst ratings available for Cyclacel Pharmaceuticals.
Recommendation Trends
| Rating | Dec '23 | Jan '24 | Feb '24 | Mar '24 | Apr '24 | May '24 |
|---|---|---|---|---|---|---|
| Strong Buy | 1 | 1 | 1 | 1 | 1 | 0 |
| Buy | 1 | 1 | 1 | 1 | 1 | 0 |
| Hold | 1 | 1 | 1 | 1 | 1 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 3 | 3 | 3 | 3 | 3 | 0 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Roth MKM | Roth MKM | Strong Buy Maintains $5,040 → $2,640 | Strong Buy | Maintains | $5,040 → $2,640 | +16,358.85% | May 3, 2024 |
| Brookline Capital | Brookline Capital | Strong Buy → Hold Downgrades n/a | Strong Buy → Hold | Downgrades | n/a | n/a | Dec 19, 2023 |
| Roth MKM | Roth MKM | Strong Buy Maintains $3,840 → $5,040 | Strong Buy | Maintains | $3,840 → $5,040 | +31,321.45% | Dec 19, 2023 |
| Oppenheimer | Oppenheimer | Buy Maintains $28,800 | Buy | Maintains | $28,800 | +179,451.12% | May 25, 2023 |
| Oppenheimer | Oppenheimer | Buy Maintains $36,000 → $28,800 | Buy | Maintains | $36,000 → $28,800 | +179,451.12% | Mar 7, 2023 |
Financial Forecast
Revenue This Year
102.00K
from 43.00K
Increased by 137.21%
Revenue Next Year
102.00K
from 102.00K
EPS This Year
-1.20
from -502.46
EPS Next Year
-1.14
from -1.20
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 |
|---|---|---|---|
| High | 105,000 | 105,000 | 84.6M |
| Avg | 102,000 | 102,000 | 82.2M |
| Low | 98,000 | 98,000 | 79.0M |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 |
|---|---|---|---|
| High | 144.2% | 2.9% | 82,852.0% |
| Avg | 137.2% | - | 80,482.4% |
| Low | 127.9% | -3.9% | 77,321.6% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 |
|---|---|---|---|
| High | -1.24 | -1.18 | 3.85 |
| Avg | -1.20 | -1.14 | 3.74 |
| Low | -1.16 | -1.10 | 3.60 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 |
|---|---|---|---|
| High | - | - | - |
| Avg | - | - | - |
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.